- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Breast MR spectroscopy reduces false positives
Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.
Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.
Researchers led by Dr. Lia Bartella performed prospective MRS scans on 27 high-risk subjects undergoing screening breast MRI. Eight were in different stages of their menstrual cycle. The investigators defined a positive MRS as having a choline peak greater than or equal to 2.
The protocol was tested in healthy breast tissue contralateral to the diseased breast. Researchers found that choline did not vary in any of the women and ruled out false positives regardless of a subject's menstrual cycle stage. The result is confidence in true-positive and true-negative findings when they perform MRS in the breast, Bartella said at the 2005 RSNA meeting.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
